RPS17P7

Across TCGA pan-cancer cohorts, RPS17P7 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated RPS17P7 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RPS17P7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPS17P7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and SKCM show a favorable association.

CHOL, TGCT, and PAAD are the cancer types where RPS17P7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.253	0.817	<.001	72	view →
TGCT	OS	Tertile	III,IV	0.003	1.000	<.001	72	view →
PAAD	DFS	Tertile	All	0.205	0.494	.002	45	view →
ACC	DFS	Tertile	All	0.227	0.784	<.001	42	view →
OV	DFS	Tertile	II,III,IV	0.427	0.552	.030	36	view →
MESO	DFS	Tertile	III,IV	0.082	0.414	.007	27	view →
READ	OS	Tertile	II,III,IV	0.287	0.829	.008	27	view →
LGG	DFS	Tertile	All	0.393	0.770	<.001	21	view →
THCA	DFS	Tertile	III,IV	0.162	0.749	.004	18	view →
HNSC	DFS	Tertile	IV	0.500	0.259	.017	9	view →
KIRC	DFS	Tertile	III,IV	0.240	0.500	.033	6	view →
SKCM	OS	Tertile	All	1.000	0.855	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

RPS17P7–CHOL (OS)

Open the CHOL breakdown →